Molecular detection of squamous cell carcinoma antigen transcripts in peripheral blood of cancer patients

Author(s):  
Nur Buyru ◽  
Hatice Tigli ◽  
Derya Duranyildiz ◽  
Nejat Dalay

AbstractThe squamous cell carcinoma antigen (SCC-Ag) has been widely applied as a serum marker in different kinds of cancer and was reported as a target gene for the detection of tumor cells in peripheral blood in cervical cancer. Nucleic acids released into the circulation are non-invasive diagnostic tools for cancer detection. The objective of this study was to determine the utility of SCC-Ag mRNA as a cancer detection marker in blood of cancer patients. For this purpose, 77 blood samples from five gastric cancer, 23 laryngeal cancer, 31 lung cancer, nine esophageal, and nine cervical cancer patients were analyzed. The

Tumor Biology ◽  
2006 ◽  
Vol 27 (3) ◽  
pp. 142-152 ◽  
Author(s):  
Eva Röijer ◽  
Henk W.A. de Bruijn ◽  
Ulrika Dahlén ◽  
Ka ten Hoor ◽  
Maria Lundin ◽  
...  

2001 ◽  
Vol 19 (19) ◽  
pp. 3960-3966 ◽  
Author(s):  
Martha D. Esajas ◽  
Jitze M. Duk ◽  
Henk W.A. de Bruijn ◽  
Jan G. Aalders ◽  
Pax H.B. Willemse ◽  
...  

PURPOSE: To investigate the contribution to recurrence detection and survival of serum squamous cell carcinoma antigen (SCC-ag) analysis in the follow-up of early-stage cervical cancer patients. PATIENTS AND METHODS: Follow-up data were evaluated in patients with early-stage squamous cell cervical cancer treated by radical hysterectomy and pelvic lymphadenectomy with or without radiotherapy. Routine serum SCC-ag determination was performed at each follow-up visit. RESULTS: Recurrent disease occurred in 35 (16%) of 225 patients and was preceded or accompanied by serum SCC-ag elevation 26 times (sensitivity, 74%). In five (14%) of these 35 patients, elevated serum SCC-ag was the first measured clinical indicator. Desite salvage therapy, all five patients died of disease. In the other 31 patients (21 with serum SCC-ag elevation), either symptoms and/or positive signs led to recurrence detection. Median survival time after recurrence was worse (9 months; range, 2 to 112+) for patients with an elevated serum SCC-ag value at recurrence in comparison with patients with normal serum SCC-ag values (20 months; range, 4 to 96; P < .01). In 23 of the 190 patients without recurrences, serum SCC-ag values became falsely elevated. In 16 of these 23 patients, the repeat sample after 6 weeks showed a normal SCC-ag, and in seven patients benign (especially skin) disorders were found. CONCLUSION: Serum SCC-ag analysis results in earlier recurrence detection in a small proportion (14%) of patients but did not contribute to better survival. As long as treatment possibilities for recurrent cervical cancer patients are not improved, serum SCC-ag analysis should not be carried out in routine follow-up.


2016 ◽  
Vol 142 (1) ◽  
pp. 115-119 ◽  
Author(s):  
Michela Salvatici ◽  
Maria T. Achilarre ◽  
Maria T. Sandri ◽  
Sara Boveri ◽  
Zanagnolo Vanna ◽  
...  

2007 ◽  
Vol 25 (2) ◽  
pp. 187-189 ◽  
Author(s):  
Katsunori Kagohashi ◽  
Hiroaki Satoh ◽  
Hiroichi Ishikawa ◽  
Morio Ohtsuka ◽  
Kiyohisa Sekizawa

Sign in / Sign up

Export Citation Format

Share Document